Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

Clinical Genitourinary Cancer

Volumn 15, Issue 1, 2017, Pages 72-76

  Hutson, Thomas E ^a   Al Shukri, Salman ^b   Stus, Viktor P ^c   Lipatov, Oleg N ^d   Shparyk, Yaroslav ^e   Bair, Angel H ^f   Rosbrook, Brad ^f   Andrews, Glen I ^f   Vogelzang, Nicholas J ^g  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Municipal Institution Dnipropetrovsk Regional Clinical Hospital na II Mechnikov   (Ukraine)

^d Republican Clinical Oncology Dispensary ^*  (Russian Federation)

^e Chemotherapy Department   (Ukraine)

^f PFIZER INC   (United States)

^g Department of Hematology Oncology   (United States)

Author keywords

Eastern Cooperative Oncology Group performance status; First line treatment; Randomized phase III trial; Tyrosine kinase inhibitor; VEGF receptor inhibitor

Indexed keywords

AXITINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ARTICLE; ASTHENIA; CANCER SURVIVAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; KIDNEY NEOPLASMS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84998865586     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.05.008     Document Type: Article

References (11)

1. 1 Hu-Lowe, D.D., Zou, H.Y., Grazzini, M.L., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14 (2008), 7272–7283.
2. 2 Hutson, T.E., Lesovoy, V., Al-Shukri, S., et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14 (2013), 1287–1294.
3. 3 Motzer, R.J., Escudier, B., Bukowski, R., et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 108 (2013), 2470–2477.
4. 4 Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009), 3584–3590.
5. 5 Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
6. 6 Motzer, R.J., Nosov, D., Eisen, T., et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31 (2013), 3791–3799.
7. 7 Sternberg, C.N., Hawkins, R.E., Wagstaff, J., et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49 (2013), 1287–1296.
8. 8 Escudier, B., Bellmunt, J., Negrier, S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28 (2010), 2144–2150.
9. 9 Rini, B.I., Halabi, S., Rosenberg, J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28 (2010), 2137–2143.
10. 10 Rini, B.I., Tomita, Y., Melichar, B., et al. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. [e-pub ahead of print] Clin Genitourin Cancer, 2016, 10.1016/j.clgc.2016.04.005.
11. 11 Motzer, R.J., Escudier, B., Tomczak, P., et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14 (2013), 552–562.